




Braille text Dots for Embossing Not for Printing

Product Name : LITACOLD Flu		Item Code : 15/1700		Item : Carton		Version: 04		Co-ordinator : Mayuri		
Pack Size : 20 x 4 Tablets		Location : Safetab		Date : 12-02-2025			Artist: Vikas			
Colours: <div><div></div> Pantone 199 C</div> <div><div></div> Pantone 871 C</div> <div><div></div> Pantone 715 C</div> <div><div></div> Black</div> BLUE WOOL TEST VALUE 5-8 (LIGHT FASTENING DATA)										
Ink: Oil Base Colours NBCL Series from SIEGWERK OR Oil based inks from DIC.			Spectro-Densitometer Delta-E reading (ΔE) for colour : NOT MORE THAN dE2.5			Softwear : CorelDraw 20				
Glossmeter reading (for white surface): NOT LESS THAN 80 %					Braille Text : Each Dot of Brille is 1.6 mm					
Actual Size: L x W x H : 108 x 77 x 75 mm				Grain Direction : Perpendicular to Crease/Perpendicular to Pasting Flap						
Material : 300 GSM ITC Cyber XL board. Overprinting area to be left unvarnished.						Style : Lock Bottom				
Varnish: U.V. Varnish			Artwork Print Size: <input checked="" type="checkbox"/> actual <input type="checkbox"/> scaled							
Instructions/Remark: Keep Overprint Preview on / Braille Text Embossing Present Instructions for Printer: ★ Avoid contamination of Benzophenone free varnish at all stages of printing activities, printing material usage, printing equipment and system etc. ★ COA should have all the details of printed label paper/ink/varnish. ● Any deviation must be brought to the notice of packaging development co-ordinator immediately. ● For any clarification, please contact packaging development co-ordinator immediately. NO CHANGES IN ARTWORK SHOULD BE DONE BY THE PRINTER The printer should verify the e-proof against the approved artwork before submitting for approval ● The printer should verify the e-proof against the approved artwork before submitting for approval and the e-proof should have printer details .				Checked By	Artist	PMD	R.A.	Production	Q.C.	Q.A.
				Bar Code	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
				Artwork	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
				Spell Check	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
				Name	Vikas					
				Signature						

Braille text as above Dots for Embossing Not for Printing


LITACOLD FLU










Product Name : LITACOLD Flu		Item Code : 15/1304		Item : Catchcover		Version : 03		Co-ordinator : Vaishali		
Pack Size : 4 Tablets		Location : Safetab		Date : 05/02/2024				Artist: Unicorn Creation		
<div>Colours:</div> <div><div><div></div><div>Pantone 199 C</div></div><div><div></div><div>Pantone 871 C</div></div><div><div></div><div>Black</div></div></div> <div>BLUE WOOL TEST VALUE 5-8 (LIGHT FASTENING DATA)</div>										
Ink: Oil Base Colours NBCL Series from SIEGWERK OR Oil based inks from DIC.			Spectro-Densitometer Delta-E reading (ΔE) for colour : NOT MORE THAN dE2.5			Softwear : CorelDraw 15				
Glossmeter reading (for white surface): NOT LESS THAN 80 %										
Actual Size: 75 X 70 X 25 mm				Grain Direction : Perpendicular to Crease/Perpendicular to Pasting Flap						
Material : 200gsm Indian art card paper.. Overprinting area to be left unvarnished.										
Varnish: U.V. Varnish				Artwork Print Size: <input checked="" type="checkbox"/> actual <input type="checkbox"/> scaled						
<div>Instructions/Remark:</div> <div>Keep Overprint Preview on / Braille Text Embossing Present</div> <div>Instructions for Printer:</div> <div>★ Avoid contamination of Benzophenone free varnish at all stages of printing activities, printing material usage, printing equipment and system etc.</div> <div>★ COA should have all the details of printed label paper/ink/varnish.</div> <div>● Any deviation must be brought to the notice of packaging development co-ordinator immediately.</div> <div>● For any clarification, please contact packaging development co-ordinator immediately.</div> <div>NO CHANGES IN ARTWORK SHOULD BE DONE BY THE PRINTER The printer should verify the e-proof against the approved artwork before submitting for approval</div> <div>● The printer should verify the e-proof against the approved artwork before submitting for approval and the e-proof should have printer details .</div>				Checked By	Artist	PMD	R.A.	Production	Q.C.	Q.A.
				Bar Code	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
				Artwork	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
				Spell Check	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
				Name	Alok	VAISHALI SAYATRU CHAUDHARI	PANKAJ SUBHASH MITTAL	SANDIP BHIKA PATIL	SAYALI HEMANT RAIBOLE	NILESH BALKRISHN A LADKAT
Signature		<div>Digitally signed by VAISHALI SAYATRU CHAUDHARI Date: 2024.02.14 10:31:29 +05'30'</div>	<div>Digitally signed by PANKAJ SUBHASH MITTAL Date: 2024.02.14 11:44:22 +05'30'</div>	<div>Digitally signed by SANDIP BHIKA PATIL Date: 2024.02.14 15:36:22 +05'30'</div>	<div>Digitally signed by SAYALI HEMANT RAIBOLE Date: 2024.02.14 11:39:46 +05'30'</div>	<div>Digitally signed by NILESH BALKRISHN A LADKAT Date: 2024.02.14 16:10:39 +05'30'</div>				
Modification Remark : Address change, dated 19/08/2020										

SATYABRATA
SANJOY
KUNDU

Digitally signed by
SATYABRATA SANJOY
KUNDU
Date: 2024.02.14 19:21:16
+05'30'



Product Name : LITACOLD Flu		Item Code : 13/0693		Item : Foil		Version : 03		Co-ordinator : Vaishali		
Pack Size : 4 Tab		Location : Safetab		Date : 05/02/2024		Artist: Unicorn Creation				
Colours: BLUE WOOL TEST VALUE 5-8 (LIGHT FASTENING DATA)				 Magenta		Softwear : CorelDraw 15				
Design : Continuous										
Foil Size: 302 ± 1 mm / Backup: 6 + 50 + 5 + 5 + 50 + 5 + 5 + 50 + 5 + 5 + 50 + 5 + 5 + 50 + 6 / Repeat Length : 40 mm										
Material : 0.03 mm Thickness - Aluminium Foil				Artwork Print Size: <input checked="" type="checkbox"/> actual <input type="checkbox"/> scaled						
<ul style="list-style-type: none">● Instructions / Remark:● Any deviation must be brought to the notice of packaging development co-ordinator immediately.● For any clarification, please contact packaging development co-ordinator immediately. <p>NO CHANGES IN ARTWORK SHOULD BE DONE BY THE PRINTER</p> <ul style="list-style-type: none">● The printer should verify the e-proof against the approved artwork before submitting for approval and the e-proof should have printer details .				Checked By	Artist	PMD	R.A.	Production	Q.C.	Q.A.
				Bar Code	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
				Artwork	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
				Spell Check	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
Name				Alok	VAISHALI SAYATRU CHAUDHARI	PANKAJ SUBHASH MITTAL	SANDIP BHIKA PATIL	SAYALI HEMANT RAIBOLE	NILESH BALKRISHNA LADKAT	
Signature					 Digitally signed by VAISHALI SAYATRU CHAUDHARI Date: 2024.02.14 10:30:55 +05'30'	 Digitally signed by PANKAJ SUBHASH MITTAL Date: 2024.02.14 11:44:43 +05'30'	 Digitally signed by SANDIP BHIKA PATIL Date: 2024.02.14 15:34:11 +05'30'	 Digitally signed by SAYALI HEMANT RAIBOLE Date: 2024.02.14 11:40:22 +05'30'	 Digitally signed by NILESH BALKRISHNA LADKAT Date: 2024.02.14 16:27:35 +05'30'	
Modification Remark : Address change, dated 19/08/2020										

SATYABRATA
SANJOY KUNDU

Digitally signed by
SATYABRATA SANJOY KUNDU
Date: 2024.02.14 19:22:03
+05'30'

Back Side : English Text



LITACOLD FLU TABLETS

Composition:
Each uncoated tablet contains:
Chlorphenamine Maleate BP 2 mg
Phenylephrine Hydrochloride BP... 5 mg
Caffeine (Anhydrous) BP 30 mg
Paracetamol BP 500 mg
Colour: Approved colour used.

PHARMACEUTICAL FORM: Tablet

LIQUID FOR ORAL USE
LITACOLD ANTICOLD SUSPENSION

COMPOSITION:
Each 5 ml contains:
Phenylephrine Hydrochloride BP.... 2.5 mg
Paracetamol BP 125 mg
Chlorphenamine Maleate BP 1 mg
Colour: Approved colour used
Excipients with a known effect: Sorbitol Solution (70%) (Non-crystallising), Sodium Methyl Paraben, Sodium Propyl Paraben, Sucrose, Glycerin

CATEGORY: Analgesic, Decongestant

PHARMACEUTICAL FORM: Liquid orals (Suspension)

ROUTE OF ADMINISTRATION: Oral

DOSAGE AND ADMINISTRATION:
LITACOLD FLU TABLETS

Children over 15 years and Adult: 1 to 2 tablets every 4 to 6 hours. Or as directed by the Physician.
LITACOLD ANTICOLD SUSPENSION
2.5ml X 3 to 4 time per day Infants (1 month-2 years): 5 ml X 3 to 4 time per day Child(over2 years): 10ml X 3 to 4 time per day Or as directed by the physician.

PHARMACODYNAMICS:

Litacold Flu Tablets exerts antihistaminic, decongestant and analgesic effects. The antihistaminic effect of Chlorphenamine maleate is by competing with histamine for H1 receptor sites on effector cells. Phenylephrine hydrochloride is sympathomimetic amines that act on alpha adrenergic receptors in the mucosa of the respiratory tract to produce vasoconstriction, which temporarily reduces the swelling associated with inflammation of the mucous membranes lining the nasal passages. Paracetamol act by inhibiting prostaglandin synthesis in the CNS & through a peripheral action by blocking pain impulse generation. Caffeine constricts cerebral vasculature with an accompanying decrease in cerebral blood flow and in the oxygen tension of the brain. Caffeine helps to relieve headache by providing a more rapid onset of action and l or enhanced pain relief with lower doses of analgesic.

PHARMACOKINETICS:

Absorption:
Chlorphenamine Maleate - Well absorbed from the gastro -intestinal tract after oral administration.
Phenylephrine Hydrochloride has reduced bioavailability from gastro-intestinal tract because of first pass metabolism by monoamine oxidase in the stomach and liver.
Caffeine-Readily and well absorbed after oral administration.
Paracetamol - Rapid and almost complete; may be decrease if paracetamol is taken following a high- carbohydrate meal.
Protein binding:
Chlorphenamine Maleate - High (72%)
Phenylephrine - 95% bound to plasma proteins. Caffeine - Adults 17% bound to plasma proteins. Paracetamol - Not significant with usual analgesic doses.
Biotransformation:
Chlorphenamine Maleate- Hepatic Phenylephrine - Gastro-intestinal & hepatic Caffeine-Hepatic.
Paracetamol - Approximately 90 - 95% of a dose is metabolized in the liver, primarily by conjugation with glucuronic acid, sulphuric acid, and cysteine. An intermediate metabolite is hepato-toxic.
Half-life:
Chlorphenamine Maleate- 21 to 27 Hours Phenylephrine Hydrochloride - 2.1 to 3.4 Hours Caffeine anhydrous-Adults 6 Hours Paracetamol-1 to 2 Hours Time to peak concentration:
Chlorphenamine Maleate - 2 to 6 Hours Phenylephrine Hydrochloride - 0.75 to 2 Hours Caffeine anhydrous-1 Hour Paracetamol-0.5 to 2 Hours Excretion: Renal

INDICATIONS:
Congestion, nasal (treatment); Congestion, sinus (treatment); and headache, sinus (treatment)
Decongestant and alagesic combinations are indicated for the temporary relief of nasal and sinus congestion and headache pain caused by sinusitis, common colds, allergy and hay fever.

CONTRA-INDICATIONS:
Contra-indicated in cardiovascular disease, diabetes mellitus, hepatic function impairment, hypertension, hyperthyroidism, and viral hepatitis.

WARNING & PRECAUTIONS:
Use with caution in patients with known hypersensitivity of any of the ingredients.

SIDE EFFECTS:
Incidence rare more frequent with high doses
• Dizziness
• Nervousness or restlessness.
• Psychotic episode (mood or mental changes usually associated with previous history of psychiatric illness.)
• Shortness of breath or troubled breathing slow or irregular heartbeat.
• CNS stimulation (hallucinations, seizures, trouble in sleeping)
• Hypertension (continuing headache, slow or fast heartbeat)
• Allergic reaction (skin rash, hives or itching) Anemia (unusual tiredness or weakness)
• Blood dyscrasias (unexplained sore throat and fever, unusual bleeding or bruising)
• Hepatitis (yellow eyes or skin)

DRUG INTERACTIONS:
Concurrent use of tricyclic antidepressant with antihistamines may potentiate the CNS depressant effects of either these medicants or antihistamines. Use of antihistamines with ototoxic medications may mask the symptoms of ototoxicity such as tinnitus, dizziness or vertigo. Use of anticholinergics with digitalis glycosides & antihypertensive drug may reduce their effects. Caffeine enhances the cardiac inotropic effects of beta-blockers. It inhibits the absorption of calcium cimetidine decreases the hepatic metabolism of caffeine resulting delayed elimination & red blood concentration. Disulfiram reduces elimination rate of caffeine by inhibiting its metabolism.

OVERDOSE AND TREATMENT:
Emptying the stomach via induction of emesis or gastric lavage. For excessive hypertensive effect An alpha-adrenergic blocker, such as Phentolamine may be administered.
The cardiac state should be monitored and serum electrolytes measured. Monitoring renal and cardiac function and administering appropriate therapy as required.
Instituting supportive treatment, including maintaining fluid and electrolyte balance, correcting hypoglycemia, and administering Vitamin K1 (if prothrombin time ratio exceeds 1.5).

STORAGE:
LITACOLD FLU TABLETS

Store below 30°C.
Protect from light.
Keep out of reach of children.

LITACOLD ANTICOLD SUSPENSION

Shake well before use.
Store below 30°C.
Protect from light.
Keep the bottle well closed.
Keep out of reach of children.

Last Revision Date:- 02/2024

GENERIC HEALTHCARE PVT. LTD.
29A, Shivaji Nagar, Pune-411005.
INDIA
export@ghpl.co
© Trade Mark

16/0824

Front Side : French Text



COMPRIMÉS DE GRIPPE LITACOLD

Composition:
Chaque comprimé non enrobé contient:
Maléate de chlorphénamine BP 2 mg
Chlorhydrate de phényléphrine BP 5 mg
Caféine (anhydre) BP 30 mg
Paracétamol BP 500 mg
Couleur: couleur approuvée utilisée.

FORMULAIRE PHARMACEUTIQUE : Comprimé

LIQUIDE POUR USAGE ORAL
SUSPENSION CONTRE LE RHUME ET LA GRIPPE LITACOLD

COMPOSITION:
Chaque 5 ml contient:
Chlorhydrate de phényléphrine BP 2.5 mg
Paracétamol BP 125 mg
Maléate de chlorphénamine BP 1 mg
Couleur: couleur approuvée utilisée
Excipients à effet notoire: Solution de sorbitol (70%) (non cristallisante), Sodium Methyl Paraben, Sodium Propyl Paraben, Sucrose, Glycérine

CATÉGORIE : Analgésique, décongestionnant

FORMULAIRE PHARMACEUTIQUE : Orales liquides (suspension)

VOIE D'ADMINISTRATION : Orale

POSOLOGIE ET ADMINISTRATION:
COMPRIMÉS DE GRIPPE LITACOLD

Enfant de plus de 15 ans et adulte: 1 à 2 comprimés toutes les 4 à 6 heures. Ou selon les directives du médecin.

SUSPENSION CONTRE LE RHUME ET LA GRIPPE LITACOLD

Nouveau-né (0-28 jours): 2,5 ml X 3 à 4 / jour Nourissons (1 mois à 2 ans): 5 ml X 3 à 4 / jour Enfant (plus de 2 ans): 10 ml X 3 à 4 / jour Ou selon les directives du médecin.

PHARMACODYNAMIQUE:

Les comprimés contre la grippe Litacold exercent des effets antihistaminiques, décongestionnants et analgésiques. L'effet antihistaminique du maléate de chlorphénamine est en concurrence avec l'histamine pour les sites récepteurs H1 sur les cellules effectrices. Le chlorhydrate de phényléphrine est des aminés a sympathomimétiques qui agissent sur les récepteurs alpha-adrénergiques dans la muqueuse des voies respiratoires pour produire une vaso-constriction, qui réduit temporairement le gonflement associé à l'inflammation des muqueuses tapissant les voies nasales. Le paracétamol agit en inhibant la synthèse des prostaglandines dans le SNC et par une action périphérique en bloquant la génération d'impulsions de douleur. La caféine resserre la vascularisation cérébrale avec une diminution correspondante du flux sanguin cérébral et de la tension d'oxygène du cerveau. La caféine aide à soulager les maux de tête en fournissant un début d'action plus rapide et / ou un soulagement accru de la douleur avec des doses plus faibles d'analgésique.

PHARMACOCINÉTIQUE:

Absorption:
Maléate de chlorphénamine - Bien absorbé par le tractus gastro-intestinal après administration orale.
Chlorhydrate de phényléphrine a une biodisponibilité réduite du tractus gastro-intestinal en raison du métabolisme de premier passage par la monoamine oxydase dans l'estomac et le foie.
Caféine - Facilement et bien absorbé après administration orale.
Paracétamol - Rapide et presque complet; peut diminuer si le paracétamol est pris après un repas riche en glucides.
Liaison protéique:
Maléate de chlorphénamine - Élevé (72%)
Phényléphrine - 95% lié aux protéines plasmatiques. Caféine - Adultes 17% liés aux protéines plasmatiques. Paracétamol - Non significatif avec les doses analgésiques habituelles.
Biotransformation:
Maléate de chlorphénamine - hépatique Phényléphrine - Gastro-intestinale et hépatique Caféine-Hépatique.
Paracétamol - Environ 90 à 95% d'une dose est métabolisée dans le foie, principalement par conjugaison avec l'acide glucuronique, l'acide sulfurique et la cystéine. Un métabolite intermédiaire est hépatotoxique.
Demi-vie:
Maléate de chlorphénamine - 21 à 27 heures Chlorhydrate de phényléphrine - 2,1 à 3,4 heures Caféine anhydre - Adultes 6 heures Paracétamol -1 à 2 heures Temps de concentration maximale:

Maléate de chlorphénamine - 2 à 6 heures Phényléphrine - 0,75 à 2 heures Chlorhydrate Caféine anhydre-1 heure Paracétamol -0,5 à 2 heures Excrétion: rénale

INDICATIONS:
Congestion nasale (traitement); Congestion, sinus (traitement); et maux de tête, sinus (traitement)
Les combinaisons décongestionnantes et alagesiques sont indiquées pour le soulagement temporaire de la congestion nasale et des sinus et des maux de tête causés par la sinusite, le rhume, l'allergie et le rhume des foins.

CONTRA-INDICATIONS:
Contre-indiqué dans les maladies cardiovasculaires, le diabète sucré, l'insuffisance hépatique, l'hypertension, l'hyperthyroïdie et l'hépatite virale.

AVERTISSEMENT ET PRÉCAUTIONS:
Utiliser avec prudence chez les patients présentant une hypersensibilité connue à l'un des ingrédients.

EFFETS SECONDAIRES:
Incidence rare plus fréquente avec des doses élevées •Vertiges
•Nervosité ou agitation.
•Épisode psychotique (humeur ou changements mentaux généralement associés avec des antécédents de maladie psychiatrique.)
•Essoufflement ou respiration difficile lente ou irrégulière battement de cœur.
•Stimulation du SNC (hallucinations, convulsions, troubles du sommeil)
•Hypertension (maux de tête continus, rythme cardiaque lent ou rapide)
•Réaction allergique (éruption cutanée, urticaire ou démangeaisons) Anémie (fatigue ou faiblesse inhabituelle)
•Dyscrasies sanguines (mal de gorge inexpliqué et fièvre, inhabituel saignement ou ecchymose)
•Hépatite (yeux ou peau jaunes)

INTERACTIONS MÉDICAMENTEUSES:

L'utilisation concomitante d'un antidépresseur tricyclique avec des antihistaminiques peut potentialiser les effets dépresseurs du SNC de ces médicaments ou des antihistaminiques. L'utilisation d'antihistaminiques avec des médicaments ototoxiques peut masquer les symptômes d'ototoxicité tels que les acouphènes, les étourdissements ou les vertiges. L'utilisation d'anticholinergiques avec des glycosides digitaliques et un antihypertenseur peut réduire leurs effets. La caféine renforce les effets inotropes cardiaques des bêta-bloquants. Il inhibe l'absorption du calcium La cimétidine diminue le métabolisme hépatique de la caféine, ce qui retarde l'élimination et la concentration sanguine rouge. Le disulfiram réduit le taux d'élimination de la caféine en inhibant son métabolisme.

SURDOSAGE ET TRAITEMENT:

Vidage de l'estomac par induction de vomissements ou lavage gastrique. En cas d'effet hypertensif excessif Un alpha-bloquant adrénergique, tel que la phentolamine, peut être administré. L'état cardiaque doit être surveillé et les électrolytes sériques mesurés. Surveiller la fonction rénale et cardiaque et administrer un traitement approprié au besoin. Instaurer un traitement de soutien, y compris maintenir l'équilibre hydroélectrolytique, corriger l'hypoglycémie et administrer de la vitamine K1 (si le rapport de temps de prothrombine dépasse 1,5).

CONSERVATION:
COMPRIMÉS DE GRIPPE LITACOLD

Conserver à une température inférieure à 30°C.
Protéger de la lumière.
Tenir hors de portée des enfants.


SUSPENSION CONTRE LE RHUME ET LA GRIPPE LITACOLD

Bien agiter avant utilisation.
Conserver à une température inférieure à 30°C.
Protéger de la lumière.
Gardez la bouteille bien fermée.
Tenir hors de portée des enfants.

Date de la dernière révision : 02/2024

GENERIC HEALTHCARE PVT. LTD.
29A, Shivaji Nagar, Pune-411005.
INDIA
export@ghpl.co
© Marque déposée

16/0824

Product Name : LITACOLD - All		Item Code : 16/0824		Item : Insert		Version: 04		Co-ordinator : Vaishali		
Pack Size : Suspension & Tablets		Location : Symbiosis/Sanpras/ Safetab/Sai Primus		Date : 09/02/2024			Artist: Unicron Creation			
Colours: BLUE WOOL TEST VALUE 5-8 (LIGHT FASTENING DATA)										
<div><div></div> Pantone 2925 C<div></div> Pantone 2756 C</div>										
Ink : Oil based Ink from DIC OR MICRO						Softwar : CorelDraw 15				
Actual Size: 140 X 230 mm		Size after folding: 70 x 39 mm		Grain Direction : Parallel to length/Parallel to printing length						
Material : Not less than 60 GSM Maplitho Paper										
Design : Folded Booklet (Back to Back Printing)				Artwork Print Size: <input checked="" type="checkbox"/> actual <input type="checkbox"/> scaled						
<div>● Instructions / Remark : Keep Overprint Preview on</div> <div>● Any deviation must be brought to the notice of packaging development co-ordinator immediately.</div> <div>● For any clarification, please contact packaging development co-ordinator immediately.</div> <div>NO CHANGES IN ARTWORK SHOULD BE DONE BY THE PRINTER</div> <div>● The printer should verify the e-proof against the approved artwork before submitting for approval and the e-proof should have printer details .</div>				Checked By	Artist	PMD	R.A.	Production	Q.C.	Q.A.
				Bar Code	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
				Artwork	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
				Spell Check	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
				Name	Alok	VAISHALI SAYATRU CHAUDHARI <small>Digitally signed by VAISHALI SAYATRU CHAUDHARI Date: 2024.02.14 10:30:52 +05'30'</small>	PANKAJ SUBHASH MITTAL <small>Digitally signed by PANKAJ SUBHASH MITTAL Date: 2024.02.14 11:45:09 +05'30'</small>	SANDIP BHIKA PATIL <small>Digitally signed by SANDIP BHIKA PATIL Date: 2024.02.14 15:33:14 +05'30'</small>	SAYALI HEMANT RAIBOLE <small>Digitally signed by SAYALI HEMANT RAIBOLE Date: 2024.02.14 11:38:57 +05'30'</small>	NILESH BALKRISHN A LADKAT <small>Digitally signed by NILESH BALKRISHNA LADKAT Date: 2024.02.14 16:25:28 +05'30'</small>
Signature										

SATYABRATA SANJOY KUNDU

Digitally signed by SATYABRATA SANJOY KUNDU
Date: 2024.02.14 19:22:46 +05'30'